Interview: Why Europe’s Biotech ‘Prime Time’ Is Now
VC Firm Sofinnova’s Chair Papiernik Speaks After New Fund Launch
The chairman of Sofinnova Partners told Scrip his newly launched biotech start-up fund aims to profit from Europe’s top science, relatively realistic asset prices, and geopolitical position between the US and China.
You may also be interested in...
As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.
Created when BetterLife bought Altum at end-July, the merged entity will now focus on advancing the acquired group’s lead asset, an inhaled form of its patented interferon a2b product, as an early treatment for COVID-19.
Roche’s etrolizumab missed primary endpoints in its Phase III study program evaluating it as maintenance therapy in moderately to severely active ulcerative colitis, a new therapeutic area for the firm.